{"log_id": 2492072356546975842, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0, "average": 0.906603, "min": 0.906603}, "location": {"width": 28, "top": 108, "height": 26, "left": 1159}, "words": "证"}, {"probability": {"variance": 0.0119, "average": 0.9513, "min": 0.567011}, "location": {"width": 743, "top": 190, "height": 37, "left": 274}, "words": "禁止本品与 MAOIS同时用于治疗精神病。正在用 MAOIS(例如,利奈唑胺或静脉注射业"}, {"probability": {"variance": 0.000143, "average": 0.995666, "min": 0.931582}, "location": {"width": 778, "top": 230, "height": 38, "left": 235}, "words": "甲蓝)治疗的患者,也不应开始本品的治疗。提供给药途径资料的亚甲蓝的所有报告都是"}, {"probability": {"variance": 0.011695, "average": 0.962732, "min": 0.385545}, "location": {"width": 781, "top": 268, "height": 40, "left": 236}, "words": "静脉给药,剂量为1mg/kg~8mg/kg。没有报告是其他途径(例如,服片剂或部组织"}, {"probability": {"variance": 0.000621, "average": 0.990085, "min": 0.873388}, "location": {"width": 771, "top": 309, "height": 39, "left": 235}, "words": "注射)给与亚甲蓝或剂量较低的。如果在服用本品的患者,有必要开始 MAOIS(例如,利"}, {"probability": {"variance": 0.005303, "average": 0.976214, "min": 0.55829}, "location": {"width": 780, "top": 350, "height": 38, "left": 237}, "words": "唑胺或静脉注射亚甲蓝)治疗,那么在 MAOIS开始治疗前,应停用本品飞见【禁忌】和【用"}, {"probability": {"variance": 8e-06, "average": 0.99515, "min": 0.990764}, "location": {"width": 81, "top": 401, "height": 24, "left": 236}, "words": "法用量】"}, {"probability": {"variance": 0.00212, "average": 0.985333, "min": 0.762957}, "location": {"width": 722, "top": 428, "height": 37, "left": 278}, "words": "如果临床认为本品与其他5一羟色胺能药,即曲坦类药、三环抗抑郁药、芬太尼、锂"}, {"probability": {"variance": 0.0039, "average": 0.985212, "min": 0.604246}, "location": {"width": 782, "top": 468, "height": 37, "left": 237}, "words": "曲马多、丁螺环酮、色氨酸和圣约翰草同时使用是合理的。应让患者了解,可能增加5-羟"}, {"probability": {"variance": 0.00692, "average": 0.983723, "min": 0.465301}, "location": {"width": 780, "top": 506, "height": 38, "left": 239}, "words": "色胺综合征的风险,特别是在治疗开始和增加剂量期间。度洛西汀与任何5-羟色胺能药同"}, {"probability": {"variance": 1e-06, "average": 0.999324, "min": 0.996848}, "location": {"width": 516, "top": 548, "height": 35, "left": 238}, "words": "时使用,如果出现上述事件,应立即停药并应对症支持治疗"}, {"probability": {"variance": 0.008408, "average": 0.982509, "min": 0.425387}, "location": {"width": 741, "top": 584, "height": 36, "left": 280}, "words": "本品与任何5羟色胺能药同时使用,如果出现上述事件,应立即停药并应对症支持治"}, {"probability": {"variance": 0, "average": 0.993753, "min": 0.993753}, "location": {"width": 24, "top": 635, "height": 23, "left": 238}, "words": "疗"}, {"probability": {"variance": 0.003354, "average": 0.980961, "min": 0.797849}, "location": {"width": 203, "top": 669, "height": 29, "left": 279}, "words": "3.严重的药物相互作用"}, {"probability": {"variance": 0.000125, "average": 0.994134, "min": 0.957785}, "location": {"width": 730, "top": 700, "height": 38, "left": 282}, "words": "与甲硫哒嗪可能的相互作用:单独使用甲硫哒嗪会延长QTc间期,出现严重的室性心"}, {"probability": {"variance": 5.8e-05, "average": 0.99584, "min": 0.964463}, "location": {"width": 676, "top": 741, "height": 36, "left": 239}, "words": "律失常,如尖端扭转型室性心动过速以及猝死。这个作用似乎与剂量有相关性"}, {"probability": {"variance": 0.000191, "average": 0.993827, "min": 0.922102}, "location": {"width": 677, "top": 778, "height": 38, "left": 303}, "words": "项体内试验显示,抑制CYP2D6的药物(如帕罗西汀)能使甲硫哒嗪血浆水平升高"}, {"probability": {"variance": 5.3e-05, "average": 0.996356, "min": 0.965991}, "location": {"width": 595, "top": 819, "height": 36, "left": 242}, "words": "因此不推荐帕罗西汀和甲硫哒嗪合用(参见【禁忌】和【注意事项】)"}, {"probability": {"variance": 2.2e-05, "average": 0.995329, "min": 0.987585}, "location": {"width": 84, "top": 866, "height": 23, "left": 313}, "words": "妊娠用药"}, {"probability": {"variance": 7e-05, "average": 0.997043, "min": 0.949038}, "location": {"width": 730, "top": 893, "height": 39, "left": 285}, "words": "致畸作用:流行病学调查显示,在妊娠头三个月暴露于抗抑郁药物的母亲所生婴儿中"}, {"probability": {"variance": 0.005539, "average": 0.978212, "min": 0.518945}, "location": {"width": 783, "top": 933, "height": 38, "left": 245}, "words": "心血管方面的先天性畸形的危险性升高(如室间隔缺损(VSDs)和房间隔缺损(ASDs)。通"}, {"probability": {"variance": 1e-05, "average": 0.998535, "min": 0.98502}, "location": {"width": 783, "top": 971, "height": 40, "left": 245}, "words": "常,间隔缺损病变的严重程度,从有症状需要外科手术治疗的病变,到没有症状或可以自然"}, {"probability": {"variance": 0.000196, "average": 0.995949, "min": 0.915877}, "location": {"width": 784, "top": 1011, "height": 39, "left": 245}, "words": "痊愈的病变。对于在服用帕罗西汀期间妊娠的妇女,应考虑该药可能对胎儿造成的伤害,只"}, {"probability": {"variance": 0.000103, "average": 0.996797, "min": 0.935513}, "location": {"width": 782, "top": 1049, "height": 38, "left": 246}, "words": "有在衡量帕罗西汀治疗受益大于潜在风险时方可继续使用,否则就需停用帕罗西汀,而选择"}, {"probability": {"variance": 0.002558, "average": 0.988146, "min": 0.684107}, "location": {"width": 780, "top": 1087, "height": 38, "left": 248}, "words": "其他抗抑郁药物(参见【注意事项】。对于计划妊娠或处于妊娠前三个月中的妇女,只有在"}, {"probability": {"variance": 0.000746, "average": 0.99349, "min": 0.852162}, "location": {"width": 555, "top": 1128, "height": 36, "left": 248}, "words": "先考虑了其他可用的治疗选择之后,才能开始使用帕罗西汀治疗"}, {"probability": {"variance": 0.000431, "average": 0.994268, "min": 0.86915}, "location": {"width": 713, "top": 1164, "height": 37, "left": 310}, "words": "项根据瑞典全国注册登记资料进行的临床试验,评价了6,896例于妊娠初期暴露于抗"}, {"probability": {"variance": 0.008577, "average": 0.978022, "min": 0.389917}, "location": {"width": 756, "top": 1203, "height": 39, "left": 249}, "words": "抑郁药物的妇女(5,123例妇女暴露于SSR,其中815例暴露于帕罗西汀)所生的婴儿"}, {"probability": {"variance": 0.000362, "average": 0.994097, "min": 0.886532}, "location": {"width": 772, "top": 1242, "height": 39, "left": 252}, "words": "与全部注册登记人群相比较,在妊娠初期暴露于帕罗西汀的婴儿中心血管畸形的风险增加"}, {"probability": {"variance": 0.00566, "average": 0.962929, "min": 0.625317}, "location": {"width": 751, "top": 1281, "height": 38, "left": 272}, "words": "主要是VSDs和ASDs)(OR1.8:95%可信区间:1.1~2.8)。在妊娠初期暴露于帕罗西"}, {"probability": {"variance": 5.9e-05, "average": 0.997687, "min": 0.951019}, "location": {"width": 773, "top": 1319, "height": 39, "left": 252}, "words": "汀的婴儿中心血管畸形比例为2%,而全部注册人群的心血管畸形比例为1%。在这些暴露于"}, {"probability": {"variance": 0.000111, "average": 0.995373, "min": 0.952478}, "location": {"width": 479, "top": 1364, "height": 32, "left": 253}, "words": "帕罗西汀的婴儿中,先天性畸形的总风险率并没有增加"}, {"probability": {"variance": 0.001028, "average": 0.986794, "min": 0.862077}, "location": {"width": 724, "top": 1398, "height": 37, "left": 294}, "words": "在一项单独的回顾性队列研究中,采用美国国家健康总署的资料评价了5,956例婴儿"}, {"probability": {"variance": 5e-05, "average": 0.996757, "min": 0.957975}, "location": {"width": 773, "top": 1438, "height": 38, "left": 255}, "words": "婴儿的母亲在妊娠的前三个月内应用了帕罗西汀或其他抗抑郁药物(应用帕罗西汀的患者"}, {"probability": {"variance": 0.006347, "average": 0.974339, "min": 0.628573}, "location": {"width": 743, "top": 1475, "height": 38, "left": 279}, "words": "15)。研究显示,与其他抗抑郁药相比较,帕罗西汀具有增加心血管畸形风险的趋势(OF"}], "language": 3}